Nanobodies Open New Avenues in Cancer Treatment: Beyond a Laboratory Bench
Bibliographic record
Abstract
Nanobody technology is a promising new approach to cancer research and treatment. Monoclonal antibodies have always been at the heart of targeted treatment, but their large size, cumbersome production, and restricted ability to penetrate tissue cause problems. Nanobodies are derived from camelid heavy-chain antibodies and have intrinsic characteristics that provide distinct benefits, including small size (15 kDa), high stability, and access to inaccessible epitopes. Their ease of production in bacterial systems further enhances their cost-effectiveness compared to conventional antibodies. Their role has been explored, from nanobody-based imaging agents that improve tumor detection to nanobody-drug conjugates that enhance targeted delivery while minimizing off-target effects. In addition, the recent expansion of their role in chimeric antigen receptor T-cell therapies, immune checkpoint blockade, and bispecific T-cell engagers highlights their increasing activity in immunotherapy. Similarly, nanobodies engineering is improving both dendritic cell vaccines and drug delivery through nanoparticle conjugation, expanding the therapeutic panorama. Here we provide remarkable findings about the versatility of Nbs-based strategies in oncology. Through their attractive characteristics, nanobodies’ therapeutics will change the way to treat cancer and provide new perspectives toward more effective and personalized medicine.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.006 |
| Scholarly communication | 0.005 | 0.011 |
| Open science | 0.001 | 0.003 |
| Research integrity | 0.004 | 0.009 |
| Insufficient payload (model declined to judge) | 0.009 | 0.004 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".